Clinical Thyroidology® for the Public Volume 11

Clinical Thyroidology® for the Public summarizes selected research studies discussed in the previous month’s issue of Clinical Thyroidology, an official publication of the American Thyroid Association®.

Search Clinical Thyroidology® for the Public

 

Volume 11 2018

  • Hyperthyroidism Awareness Month

    In this issue Volume 11 Issue 11, the studies ask the following questions:

    1. Can we identify patients at risk for Graves’ eye disease?
    2. Are patients with a suppressed TSH being appropriately evaluated for hyperthyroidism?
    3. Should the goal of definitive therapy for hyperthyroidism be hypothyroidism?
    4. Is there a better way to differentiate between the 2 types of amiodaroneinduces thyrotoxicosis?
    5. Is there a new formulation for thyroid hormone therapy in the future?
    6. Is it worth it to follow thyroglobulin levels in thyroid cancer patients that only have undergone a lobectomy?

  • Thyroid Cancer Awareness Month

    In this issue Volume 11 Issue 10, the studies ask the following questions:

    1. Is there an association between thyroid dysfunction in the mother and the development of autism and ADHD in the children?
    2. Does the type of nodule biopsy technique affect the frequency of non-diagnostic samples?
    3. Are small bright spots noted on ultrasound associated with thyroid cancer?
    4. Can the ATA ultrasound classification system help determine the risk of cancer in indeterminate thyroid nodules?
    5. Can a new version of a molecular marker assay improve the diagnosis of cancer in indeterminate thyroid nodules?
    6. Is survival the best endpoint in determining the extent of surgery in medullary thyroid cancer?

  • In this issue Volume 11 Issue 9, the studies ask the following questions:

    1. Can we predict the length of treatment-free survival in patients with thyroid cancer?
    2. Can the TIRADS imaging criteria decrease the number of thyroid nodule biopsies without missing any cancers?
    3. Can the TIRADS imaging criteria be applied to small thyroid nodules?
    4. Does the timing of radioactive iodine therapy after surgery affect outcomes in patients with thyroid cancer?
    5. What are the implications of residual cancer in lymph nodes after surgery for patients with intermediate to high risk thyroid cancer?

  • In this issue Volume 11 Issue 8, the studies ask the following questions:

    1. Can we predict the likelihood of developing neonatal Graves’ disease prior to the onset of symptoms?
    2. Are thyroid levels in the mother associated with child scores on standardized tests?
    3. How much do thyroid tests change in individuals without thyroid disease?
    4. Is NIFTP a benign subtype of papillary thyroid cancer?
    5. Should NIFTP still be considered a cancer?
    6. Is active surveillance appropriate for small, low risk thyroid cancers?

  • In this issue Volume 11 Issue 7, the studies ask the following questions:

    1. Does selenium improve the response to therapy in patients with Graves’ disease?
    2. Does exposure to endocrine disrupting chemicals in the environment alter thyroid levels during pregnancy?
    3. Does the rate of nodule growth predict risk of cancer?
    4. Does TSH levels affect the growth of small papillary thyroid cancers that are followed by ultrasound instead of surgery?
    5. Is management of thyroid nodules different in patients >70 years old?
    6. Does minimal extension of thyroid cancer outside the thyroid affect thyroid cancer recurrence or death?

  • In this issue Volume 11 Issue 6, the studies ask the following questions:

    1. What is the best method of surveillance for thyroid cancer in survivors of childhood cancer?
    2. What role does body play in levothyroxine dosing?
    3. Do small changes in the dose of levothyroxine affect quality of life?
    4. Does Graves’ disease increase a patient’s risk of suicide?
    5. Does the amount of surgeries performed annually by a surgeon affect the rate of recurrence of thyroid cancer?

  • In this issue Volume 11 Issue 5, the studies ask the following questions:

    1. Does selenium help preserve salivary gland problems after radioactive iodine therapy?
    2. What are the effects of radioactive iodine therapy on fertility in women?
    3. What is the risk of hypoparathyroidism after total thyroidectomy?
    4. Do calcifications in thyroid nodules on ultrasound always indicate thyroid cancer?
    5. Does the extent of initial surgery affect overall survival in low risk thyroid cancers?

  • In this issue Volume 11 Issue 4, the studies ask the following questions:

    1. What is the best treatment for hypothyroidism?
    2. Are thyroid hormone levels in the normal range a risk factor for atrial fibrillation?
    3. Does levothyroxine treatment affect the risk of preterm delivery in hypothyroid women?
    4. Do probiotics affect the absorption of levothyroxine?
    5. Does surgery for hyperthyroidism provide a lower risk for heart problems than RAI therapy?

  • In this issue Volume 11 Issue 3, the studies ask the following questions:

    1. Should US newborn thyroid screening programs be standardized?
    2. Should thyroid testing in the US be standardized?
    3. Does thyroid abnormalities in the mother after heart disease risk in their children?
    4. Are the ATA guidelines on ultrasound risk assessment of thyroid nodules valid?
    5. What is the prognostic significance of thyroid incidentalomas identified on PET scans?
    6. Is a 2nd radioactive iodine therapy helpful with patients with recurrent thyroid cancer in the neck?

  • In this issue Volume 11 Issue 2, the studies ask the following questions:

    1. Should TSH testing for thyroid disease become standardized?
    2. Can molecular testing help identify benign nodules?
    3. Can NIFTP be diagnosed without surgery?
    4. Can low risk small papillary cancer be followed without surgery?
    5. Is multifocal papillary thyroid cancer a risk factor for more aggressive disease?

  • In this issue Volume 11 Issue 1, the studies ask the following questions:

    1. Is subclinical thyroid disease associated with a risk of dementia?
    2. Are thyroid hormone levels associated with a risk death in the elderly?
    3. How common are liver abnormalities in patients with hyperthyroidism?
    4. How can parathyroid lesions be distinguished from thyroid nodules?
    5. Can we identify patients that will benefit the most from aggressive chemotherapy?

Clinical Thyroidology® for the Public Past Issues

2014 – 2017

VOLUME 10

VOLUME 9

VOLUME 8

VOLUME 7

2011 – 2013

VOLUME 6

VOLUME 5

VOLUME 4

2008 – 2010

VOLUME 3

VOLUME 2

VOLUME 1

Editor
Alan P. Farwell, MD, FACE
Boston Medical Center
Boston University School of Medicine

Editorial Board
Jessie Block-Galaraza, MD, Albany, NY
Gary Bloom, New York, NY
Alina Gavrila, MD, MMSC, Boston, MA
Melanie Goldfarb, MD, MS, FACS, FACE,
Santa Monica, CA
Shirin Haddady, MD, MPH, Boston, MA
Sun Lee, MD, Boston, MA
Joshua Klopper, MD, Denver, CO
Angela Leung, MD, Los Angeles, CA
Priya Mahajan, MD, Houston, TX
Maria Papaleontiou, MD, Ann Arbor, MI
Jason D. Prescott, MD PhD, Baltimore, MD
Marjorie Safran, MD, Worcester, MA
Anna M. Sawka, MD, Toronto, ON, Canada
Phillip Segal, MD, Toronto, ON, Canada
Vibhavsu Sharma, MD, Albany, NY
Ebru Sulanc, MD , Detroit, MI
Valentina Tarasova, MD, Tampa, FL
Whitney Woodmansee, MD, Gainesville, FL

We welcome your feedback and suggestions. Let us know what you want to see in this publication.

Feedback & Suggestions

Published monthly and distributed free of charge to Friends of the ATA

Sign Up Here

Give Direct

IMA Outstanding Achievement Award